Geologists from the University of Hong Kong (HKU) have made a breakthrough in understanding how Earth's early continents ...

Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

Mantle Cell Lymphoma Video Perspectives Stephen M. Ansell, MD, PhD Disclosures ... February 21, 2025 ...

Feb. 5. 2025 – The FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL). This treatment is for people who are newly diagnosed or haven't had ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

This approval also converts CALQUENCE's accelerated approval for patients with mantle cell lymphoma who have received at least one prior therapy, granted in October 2017, to full approval for use ...

Potential patches of Earth's ancient crust, sometimes called "sunken worlds," may have just been discovered deep within the mantle, thanks to a new way of mapping the inside of our planet.

The early days of mantle cell lymphoma were in the 1980s, said Timothy Fenske, a physician and professor at the Medical College of Wisconsin who presented the study at the annual American Society ...

Mantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatment appears to be successful, the cancer often returns and is difficult to cure. A new therapy ...

As an aside, especially at least in mantle cell lymphoma [MCL], the good thing is while we get a lot of that competitive binding with a 2.5-mg dose because of how fast the body clears obinutuzumab ...

The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said ...

The Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) who have ...